Cabio Biotech Wuhan Co Ltd (688089) - Net Assets
Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has net assets worth CN¥1.64 Billion CNY (≈ $239.89 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.82 Billion ≈ $266.73 Million USD) and total liabilities (CN¥183.42 Million ≈ $26.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cabio Biotech Wuhan Co Ltd (688089) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.64 Billion |
| % of Total Assets | 89.94% |
| Annual Growth Rate | 12.53% |
| 5-Year Change | 18.59% |
| 10-Year Change | 342.34% |
| Growth Volatility | 39.36 |
Cabio Biotech Wuhan Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Cabio Biotech Wuhan Co Ltd for the complete picture of this company's asset base.
Annual Net Assets for Cabio Biotech Wuhan Co Ltd (2013–2024)
The table below shows the annual net assets of Cabio Biotech Wuhan Co Ltd from 2013 to 2024. For live valuation and market cap data, see Cabio Biotech Wuhan Co Ltd (688089) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.57 Billion ≈ $229.67 Million |
+5.06% |
| 2023-12-31 | CN¥1.49 Billion ≈ $218.60 Million |
+4.83% |
| 2022-12-31 | CN¥1.43 Billion ≈ $208.53 Million |
+3.13% |
| 2021-12-31 | CN¥1.38 Billion ≈ $202.20 Million |
+4.40% |
| 2020-12-31 | CN¥1.32 Billion ≈ $193.67 Million |
+5.92% |
| 2019-12-31 | CN¥1.25 Billion ≈ $182.85 Million |
+137.47% |
| 2018-12-31 | CN¥526.20 Million ≈ $77.00 Million |
+13.31% |
| 2017-12-31 | CN¥464.39 Million ≈ $67.96 Million |
+15.35% |
| 2016-12-31 | CN¥402.60 Million ≈ $58.91 Million |
+13.46% |
| 2015-12-31 | CN¥354.83 Million ≈ $51.92 Million |
-23.84% |
| 2014-12-31 | CN¥465.90 Million ≈ $68.18 Million |
+8.79% |
| 2013-12-31 | CN¥428.24 Million ≈ $62.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cabio Biotech Wuhan Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 91.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥503.35 Million | 32.35% |
| Common Stock | CN¥168.31 Million | 10.82% |
| Other Comprehensive Income | CN¥88.07 Million | 5.66% |
| Other Components | CN¥796.36 Million | 51.18% |
| Total Equity | CN¥1.56 Billion | 100.00% |
Cabio Biotech Wuhan Co Ltd Competitors by Market Cap
The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VT Industrial Technology Co Ltd
SHE:300707
|
$392.41 Million |
|
Miwon Specialty Chemical Co Ltd
KO:268280
|
$392.51 Million |
|
Vox Royalty Corp.
TO:VOXR
|
$392.61 Million |
|
Yangzhou Chenhua New Material Co Ltd
SHE:300610
|
$392.97 Million |
|
IndoStar Capital Finance Limited
NSE:INDOSTAR
|
$392.28 Million |
|
Cadiz Inc
NASDAQ:CDZI
|
$392.28 Million |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
$392.17 Million |
|
Boss Energy Ltd
AU:BOE
|
$392.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cabio Biotech Wuhan Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,476,352,721 to 1,556,087,313, a change of 79,734,592 (5.4%).
- Net income of 124,212,718 contributed positively to equity growth.
- Dividend payments of 34,015,413 reduced retained earnings.
- Share repurchases of 10,815,055 reduced equity.
- Other comprehensive income increased equity by 8,542,146.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥124.21 Million | +7.98% |
| Dividends Paid | CN¥34.02 Million | -2.19% |
| Share Repurchases | CN¥10.82 Million | -0.7% |
| Other Comprehensive Income | CN¥8.54 Million | +0.55% |
| Other Changes | CN¥-8.19 Million | -0.53% |
| Total Change | CN¥- | 5.40% |
Book Value vs Market Value Analysis
This analysis compares Cabio Biotech Wuhan Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥9.42 | CN¥15.93 | x |
| 2014-12-31 | CN¥10.25 | CN¥15.93 | x |
| 2015-12-31 | CN¥7.81 | CN¥15.93 | x |
| 2016-12-31 | CN¥3.19 | CN¥15.93 | x |
| 2017-12-31 | CN¥3.69 | CN¥15.93 | x |
| 2018-12-31 | CN¥4.19 | CN¥15.93 | x |
| 2019-12-31 | CN¥7.43 | CN¥15.93 | x |
| 2020-12-31 | CN¥7.84 | CN¥15.93 | x |
| 2021-12-31 | CN¥11.30 | CN¥15.93 | x |
| 2022-12-31 | CN¥8.45 | CN¥15.93 | x |
| 2023-12-31 | CN¥8.72 | CN¥15.93 | x |
| 2024-12-31 | CN¥9.27 | CN¥15.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cabio Biotech Wuhan Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.98%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.36%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.08x
- Recent ROE (7.98%) is below the historical average (9.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 10.91% | 23.34% | 0.43x | 1.09x | CN¥3.88 Million |
| 2014 | 8.08% | 20.19% | 0.37x | 1.09x | CN¥-8.93 Million |
| 2015 | 5.51% | 10.79% | 0.41x | 1.24x | CN¥-15.94 Million |
| 2016 | 11.64% | 24.74% | 0.40x | 1.18x | CN¥6.60 Million |
| 2017 | 14.13% | 28.78% | 0.45x | 1.09x | CN¥19.22 Million |
| 2018 | 18.42% | 33.90% | 0.49x | 1.10x | CN¥44.33 Million |
| 2019 | 9.47% | 37.93% | 0.24x | 1.04x | CN¥-6.66 Million |
| 2020 | 9.91% | 40.37% | 0.23x | 1.05x | CN¥-1.21 Million |
| 2021 | 9.31% | 36.62% | 0.24x | 1.05x | CN¥-9.52 Million |
| 2022 | 4.54% | 14.85% | 0.27x | 1.14x | CN¥-77.52 Million |
| 2023 | 6.19% | 20.59% | 0.28x | 1.09x | CN¥-56.26 Million |
| 2024 | 7.98% | 22.36% | 0.33x | 1.08x | CN¥-31.40 Million |
Industry Comparison
This section compares Cabio Biotech Wuhan Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,387,359,426
- Average return on equity (ROE) among peers: 2.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cabio Biotech Wuhan Co Ltd (688089) | CN¥1.64 Billion | 10.91% | 0.11x | $392.34 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $948.24 Million | -53.63% | 0.17x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $304.67 Million | -9.25% | 1.53x | $444.78 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.06 Billion | 8.06% | 0.08x | $444.44 Million |
| Chengzhi Shareholding Co Ltd (000990) | $15.52 Billion | 0.71% | 0.30x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $3.87 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.25 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $5.41 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $568.58 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $1.91 Billion |
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.